{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:16:32Z","timestamp":1769580992311,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/mnm.0b013e32835ae523","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T08:47:34Z","timestamp":1351586854000},"page":"19-24","source":"Crossref","is-referenced-by-count":19,"title":["I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity"],"prefix":"10.1097","volume":"34","author":[{"given":"Marcel P.M.","family":"Stokkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"de Wit-van der Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Boekhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210212","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12032-011-9897-9","article-title":"Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better.","volume":"29","author":"Petrelli","year":"2012","journal-title":"Med Oncol"},{"key":"R2-4-20210212","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","article-title":"Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.","volume":"21","author":"Costa","year":"2010","journal-title":"Ann Oncol"},{"key":"R3-4-20210212","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy.","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R4-4-20210212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0025-6196(11)60840-9","article-title":"Trastuzumab-induced cardiotoxicity: heart failure and crossroads.","volume":"83","author":"Sengupta","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R5-4-20210212","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-4-20210212","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00259-007-0639-3","article-title":"I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study.","volume":"25","author":"Agostini","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-4-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00003072-199203000-00001","article-title":"I-123-MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity.","volume":"17","author":"Valdes Olmos","year":"1992","journal-title":"Clin Nucl Med"},{"key":"R8-4-20210212","first-page":"2044","article-title":"Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity.","volume":"36","author":"Carrio","year":"1995","journal-title":"J Nucl Med"},{"key":"R9-4-20210212","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1071-3581(96)90022-7","article-title":"Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy.","volume":"3","author":"Lekakis","year":"1996","journal-title":"J Nucl Cardiol"},{"key":"R10-4-20210212","first-page":"49","article-title":"Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy.","volume":"27","author":"Takano","year":"1996","journal-title":"J Cardiol"},{"key":"R11-4-20210212","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MNM.0b013e328337a99b","article-title":"Mathematical methods to determine quantitative parameters of myocardial I123-MIBG studies: review of literature.","volume":"31","author":"van der Veen","year":"2010","journal-title":"Nucl Med Commun"},{"key":"R12-4-20210212","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10741-010-9196-0","article-title":"The role of nuclear medicine imaging in the failing heart: myocardial blood flow, sympathetic innervation and future applications.","volume":"16","author":"Boogers","year":"2011","journal-title":"Heart Fail Rev"},{"key":"R13-4-20210212","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","article-title":"Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (adreview myocardial imaging for risk evaluation in heart failure) study.","volume":"55","author":"Jacobson","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R15-4-20210212","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2967\/jnumed.107.047548","article-title":"Prognostic values of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction.","volume":"49","author":"Kasama","year":"2008","journal-title":"J Nucl Med"},{"key":"R16-4-20210212","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/ncponc1090","article-title":"Therapy insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects.","volume":"5","author":"Popat","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"R17-4-20210212","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2011.74","article-title":"Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.","volume":"90","author":"Van Hasselt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R19-4-20210212","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment.","volume":"37","author":"Senkus","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R20-4-20210212","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/CCO.0b013e32833ab6f1","article-title":"Insights into cardiovascular side-effect of modern anticancer therapeutics.","volume":"22","author":"Stortecky","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"R21-4-20210212","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00259-008-0976-x","article-title":"How to use myocardial 123I-MIBG scintigraphy in chronic heart failure.","volume":"36","author":"Agostini","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-4-20210212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12350-011-9438-0","article-title":"Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake.","volume":"19","author":"Chen","year":"2012","journal-title":"J Nucl Cardiol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006231-201301000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:49:47Z","timestamp":1618037387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201301000-00004"}},"subtitle":["the first experience"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e32835ae523","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}